Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

34.27 -0.25 (-0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
Exposures COVID-19
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. 
Via InvestorPlace
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Find out why analysts have such high expectations for these stocks. 
Via The Motley Fool
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
Via Benzinga
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
From Genentech
Via Business Wire
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)... 
Via Benzinga
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
From Genentech
Via Business Wire
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme 
Via Benzinga
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t 
Via Benzinga
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,  
Via Benzinga
Exposures Product Safety
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
What's Going On With Sonnet BioTherapeutics Stock Today?
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 (IL12-FHAB) in combination with Roche... 
Via Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Is TTOO Stock Really Worth $5? Or Just 5 Cents?
TTOO stock has been red hot in recent days, but the story of MULN stock should give speculative investors in T2 Biosystems caution. 
Via InvestorPlace
Is AbbVie Still a Good Dividend Stock to Buy?
Find out if AbbVie can overcome sinking sales of its top-selling product. 
Via The Motley Fool
Why Is Aravive Stock Sinking Today?
Aravive Inc (NASDAQ: ARAV) shares plunged after the company's Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary... 
Via Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
Wall Street Journal 
Via Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.